Immunoscore and Its Predictive Value for Colorectal Cancer


Authors: E. Závadová 1;  J. Špaček 1;  M. Vočka 1;  B. Konopásek 1;  T. Fučíková 2;  I. Netíková 1,3,4;  P. Dundr 5;  H. Skálová 5;  L. Petruželka 1
Authors‘ workplace: Onkologická klinika 1. LF UK a VFN v Praze 1;  Ústav imunologie a mikrobiologie, 1. LF UK a VFN v Praze 2;  Oddělení klinické farmakologie a farmacie, VFN v Praze 3;  Farmakologický ústav, 1. LF UK a VFN v Praze 4;  Ústav patologie, 1. LF UK a VFN v Praze 5
Published in: Klin Onkol 2015; 28(Supplementum 4): 82-85
Category: Specials
doi: 10.14735/amko20154S82

Overview

Recent studies suggest that immune‑ classification (immunoscore) in cancer patients has a prognostic value in some cases that seems to be superior to the AJCC/ UICC TNM  classification. The clinical outcome can vary significantly among patients with a particular diagnosis within the same TNM stage. Immunoscore methodology quantifies and detects different types of immune cells in tumor tissue, and also determines the density of their infiltration and localization at the tumor site. Currently within an international collaboration of 23 centers in 17 countries (including our department), immunoscore is being evaluated in more than 7,000 colorectal cancer patients in terms of the tumor microenvironment, focusing on the presence of immune cells both in the tumor tissue and the tumor invasive margin. Immunoscore results are assessed in correlation with: 1. patient‘s response to the treatment, 2. rate of progression, disease prognosis and other immune parameters. It appears that the TNM classification and tumor invasiveness is statistically dependent on the immune response of the patient (there is an inverse correlation between the density of the infiltration of CD 8+, CD3+ lymphocytes and the tumor stage). High densities of T-lymphocytes (CD8+, CD3+) both in the core and the invasive margin of the primary tumor are associated with longer‑term asymptomatic survival, overall survival, lower risk of relapse and reduced likelihood of metastases. The project of the international collaboration aims to introduce immunoscore in routine diagnostics.

Keywords:
immunoscore –  TNM –  VEGF –  TGF‑β –  CD3+ lymphocytes –  CD8+ lymphocytes

This project was supported by AZV CR 15-28188A, the League Against Cancer and PRVOUK-P-27//LF1/1.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
4. 8. 2015

Accepted:
13. 9. 2015


Sources

1. Galon J, Mlecnik B, Bindea G et al. Towards the introduction of the ‚immunoscore‘ in the classification of malignant tumours. J Pathol 2014; 232(2): 199– 209. doi: 10.1002/ path.4287.

2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646– 674. doi: 10.1016/ j.cell.2011.02.013.

3. Matsumura Y, Kobayashi T, Ichiyama K et al. Selective expansion of foxp3 positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3deficient dendritic cells. J Immunol 2007; 179(4): 2170– 2179.

4. Bates GJ, Fox SB, Han C et al. Quantification of regulatory T cells enables the identification of high‑risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24(34): 5373– 5380.

5. Logan‑ Collins JM, Lowy AM, Robinson‑ Smith TM et al. VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol 2008; 15(3): 738– 744.

6. Locker GY, Hamilton S, Harris J et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24(33): 5313– 5327.

7. Weitz J, Koch M, Debus J et al. Colorectal cancer. Lancet 2005; 365(9454): 153– 165.

8. Nagtegaal ID, Quirke P, Schmoll HJ. Has the new TNM classification for colorectal cancer improved care? Nat Rev Clin Oncol 2011; 9(2): 119– 123.

9. Mlecnik B, Bindea G, Pages F et al. Tumor immunosurveillance in human cancers. Cancer Metastasis Rev 2011; 30(1): 5– 12. doi: 10.1007/ s10555‑ 011‑ 9270‑ 7.

10. Bindea G, Mlecnik B, Fridman WH et al. Natural immunity to cancer in humans. Curr Opin Immunol 2010; 22(2): 215– 222. doi: 10.1016/ j.coi.2010.02.006.

11. Kopecký J, Slovacek L, Priester P et al. Changes in immune reactivity in cancer patients. Klin Onkol 2012; 25(2): 97– 102. doi: 10.14735/ amko201297.

12. Galon J, Costes A, Sanchez‑ Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313(5795): 1960– 1964.

13. Mlecnik B, Tosolini M, Kirilovsky A et al. Histopathologic‑based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29(6): 610– 618. doi: 10.1200/ JCO.2010.30.5425.

14. Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353(25): 2654– 2666.

15. Melichar B, Študentová H, Kalábová H et al. Predictive and prognostic significance of tumor‑ infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy. Anticancer Res 2014; 34(3): 1115– 1125.

16. Čermáková P, Melichar B, Tomšová M et al. Prognostic significance of CD3+ tumor‑ infiltrating lymphocytes in patients with endometrial carcinoma. Anticancer Res 2014; 34(10): 5555– 5561.

17. Denkert C, Loibl S, Noske A et al. Tumor‑associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28(1): 105– 113. doi: 10.1200/ JCO.2009.23.7370.

18. Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumor‑ infiltrating lymphocytes in a phase IIIrandomized adjuvant breast cancer trial in node‑ positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin‑based chemotherapy: BIG 02 98. J Clin Oncol 2013; 31(7): 860– 867. doi: 10.1200/ JCO.2011.41.0902.

19. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8(3): 151– 160. doi: 10.1038/ nrclinonc.2010.223.

20. Nosho K, Baba Y, Tanaka N et al. Tumour‑ infiltrating T‑ cell subsets, molecular changes in colorectal cancer and prognosis: cohort study and literature review. J Pathol 2010; 222(4): 350– 366. doi: 10.1002/ path.2774.

21. Ogino S, Nosho K, Irahara N et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 2009; 15(20): 6412– 6420. doi: 10.1158/ 1078‑ 0432.CCR‑ 09‑ 1438.

22. Guidoboni M, Gafa R, Viel A et al. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol 2001; 159(1): 297– 304.

23. Tougeron D, Fauquembergue E, Rouquette A et al. Tumor‑ infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod Pathol 2009; 22(9): 1186– 1195. doi: 10.1038/ modpathol.2009.80.

24. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti‑PD‑ L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366(26): 2455– 2465. doi: 10.1056/ NEJMoa1200694.

25. Hodi FS, O‘Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): 711– 723. doi: 10.1056/ NEJMoa1003466.

26. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti‑PD‑ 1 antibody in cancer. N Engl J Med 2012; 366(26): 2443– 2454. doi: 10.1056/ NEJMoa1200690.

27. Galon J, Pages F, Marincola FM et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012; 10: 205. doi: 10.1186/ 1479‑ 5876‑ 10‑ 205.

28. Galon J, Pages F, Marincola FM et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012; 10: 1. doi: 10.1186/ 1479‑ 5876‑ 10‑ 1.

29. Väyrynen JP, Vornanen JO, Sajanti S et al. An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer. Virchows Arch 2012; 460(5): 455– 465. doi: 10.1007/ s00428‑ 012‑ 1232‑ 0.

Labels
Paediatric clinical oncology Surgery Clinical oncology

Article was published in

Clinical Oncology

Issue Supplementum 4

2015 Issue Supplementum 4

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account